

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

<b>Research &amp; Professional Experience:</b>	
MOORE Clinical Research, Inc, Clinical Investigator	Dec 2014–Present
Locum Tenens Physician, Tampa, FL	June 2013–Nov 2014
Chief Health Officer, Florida Department of Corrections, Hillsborough County, FL	Sep 2003–Oct 2012
Private Practice, Ob/Gyn and Family Medicine, Zephyrhills, FL	Sep 1983–Sep 2003
Medical Director, East Pasco Public Health Clinic, Dade City, FL	Sep 1981–Sep 1983
Physician, Ob/Gyn & ER, Jackson Memorial Hospital, Dade City, FL	July 1979–Sep 1981
Research Chemist, Rohm & Haas Company, Philadelphia, PA	Sep 1960–Sep 1971

<b>Education:</b>	
Eastern Virginia Medical School, Norfolk, Va, Residency Program Ob/Gyn	Sep 1975–May 1979
Temple University Medical School, Philadelphia, PA, Graduate School of Medicine	1971–May 1975
The Agriculture and Technical University, Greensboro, NC, BS Chemistry	May 1960

<b>Licenses/Certifications:</b>	
Florida Medical Doctor, ME 35623	January 2020
United States Department of Justice, DEA Registration, FS2528579	
BLS, Healthcare Provider	October 2019
Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations	July 2017

<b>Training:</b>	
Comprehensive SOP Review	January 2019
Comprehensive SOP Review	January 2018
Comprehensive SOP Review	January 2017
Basic HIPAA Training	January 2017
GCP Training, NIH	October 2016
Comprehensive SOP Review	January 2016
Rosacea Clinical Assessment Training	August 2015
Atopic Dermatitis Clinical Assessment Training	August 2015
CITI Program: GCP for Clinical Trials with Investigational Drugs and Biologics	August 2015
Acne Lesion Count, IGA and Severity Training & Validation	June 2015
Actinic Keratosis Clinical Assessment Training	May 2015
Mycology Certification Training (Specimen Collection, KOH Interpretation, Differential)	April 2015
Plaque Psoriasis Clinical Assessment Training (IGA, plaque elevation, PASI scoring)	January 2015
Acne Vulgaris Clinical Assessment Training (IGA, lesion counts)	January 2015
Adverse Event Determination and Reporting	December 2014
Comprehensive SOP Review	December 2014
Protection of Human Research Subjects Key Investigator & ICH/GCP Training	December 2014
Customer Service Training	December 2014
Good Documentation Practices	December 2014
Human Subject Assurance Training	December 2014
Obtaining Informed Consent	December 2014
OSHA Hazardous Materials Training	December 2014

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

Signature

Date

***Clinical Trial Experience:***

- ACNE VULGARIS (Validated Acne Rater)

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study, Comparing Clindamycin 1% to Cleocin T (XXXX, Clindamycin 1% Gel) and Both Active Treatments to a Vehicle Control in the Treatment of Acne." 2018

"A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris." 2018

"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of UHE-101 Cream 1% When Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled Parallel-Group Study, Comparing Tretinoin Cream, 0.1% (XXXX) to Retin-A® (Tretinoin) Cream, 0.1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled Parallel-Group Study, Comparing Tretinoin Cream, 0.05% (XXXX) to Retin-A® (Tretinoin) Cream, 0.05% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2017

"A Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Study of Olumacostat Glasaretil in Subjects with Acne Vulgaris." 2017

"An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects with Acne Vulgaris." 2017

"A Multicenter, Randomized, Double Blind, Parallel, Placebo Controlled, Clinical Endpoint Study to Determine the Therapeutic Equivalence of Test Product Benzoyl Peroxide (5%) + Clindamycin Phosphate (Equivalent to 1% Base) Gel and Reference Product BenzaClin® Topical Gel in Patients with Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Adapalene Spray, 0.3% in the Treatment of Acne Vulgaris." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone (Dapsone) Gel, 7.5%, XXXX, and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2016

"A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily XXXX and Vehicle Gel in the Treatment of Acne Vulgaris." 2016

"A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products XXXX and XXXX for the Treatment of Acne Vulgaris for 12 Weeks." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing Dapsone 5% Gel, (XXXX) to Aczone® (XXXX Dapsone Gel 5%) and Both Active Ingredients Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris." 2016

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris." 2016

"A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17 $\alpha$ -Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris." 2015

"An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17 $\alpha$ -Propionate (CB-03-01) Cream, 1% Applied Twice Daily for up to 12 months in Subjects with Facial Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Dapsone Gel, 5% (XXX) to Aczone<sup>®</sup> (Dapsone) Gel, 5%, (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (XXXX Laboratories UT, Inc.) to Epiduo<sup>®</sup> Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris." 2015

"A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects with Moderate to Severe Acne Vulgaris." 2015

"A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Clindamycin and Benzoyl Peroxide Gel 1%/5% (XXXX Pharmaceuticals, Inc.) to Benzaclin<sup>®</sup> (Clindamycin, as Phosphate, 1% and Benzoyl Peroxide 5%) Topical Gel (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel, 0.35/2.5% (XXXX Pharmaceuticals USA, Inc.) to Epiduo<sup>®</sup> Forte (Adapalene and Benzoyl Peroxide Gel 0.3%/2.5%, XXXX Laboratories, L.P.) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Double-Blind, Randomized, Placebo Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne." 2015

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (XXXX) to the Marketed Product BenzaClin<sup>®</sup> Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (XXXX) in the Treatment of Acne Vulgaris." 2015

"A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of DRM01B Topical Gel in Subjects with Acne Vulgaris." 2015

"A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (XXXX Pharmaceuticals, Inc.) to Onexton<sup>™</sup> Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% XXXX Pharmaceuticals LLC) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (XXXX Pharmaceuticals, Inc.) to Tactupump<sup>™</sup> (XXXX Inc., Adapalene and Benzoyl Peroxide Topical Gel, 0.1%/2.5% w/w) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

XXXX Acne Product Study for the Alleviation of Facial Acne and Associated Redness and Inflammation

"A single-site, randomized, single-blind, comparative therapeutic clinical study against open-label Proactiv+<sup>®</sup>" 2015

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A Randomized, Double-Blind, Multiple-Center, Placebo-Controlled Study Comparing Clindamycin and Benzoyl Peroxide Gel 1%/5% (XXXX Pharmaceuticals, Inc.) to Benzaclin® (Clindamycin 1%/Benzoyl Peroxide) Topical Gel (XXXX) in the Treatment of Acne Vulgaris." 2015

"A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris." 2014

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% (XXXX) to Differin® (XXXX Adapalene Gel 0.3%) and Both Active Ingredients to a Placebo Control in the Treatment of Acne Vulgaris." 2014

- PSORIASIS

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018

"A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to MC2-01 Cream Vehicle and Active Comparator in Subjects with Mild-to-Moderate Psoriasis Vulgaris." 2017

"A Multi-Center, Open Label, Baseline-Controlled Study of PSORX Lotion in Subjects with Plaque Psoriasis." 2017

"A Multi-Center, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Foam, 0.05% Versus Vehicle Foam in Subjects with Plaque Psoriasis." 2016

"A Multi-Center, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis." 2016

"A Phase 2, Multicenter, Evaluator-Blinded, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion with Tazorac® (tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis." 2016

"A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days." 2016

"A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis." 2015

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone Topical Spray, 0.15% (XXX Pharmaceuticals, U.S.A., Inc.) in Patients with Mild to Moderate Plaque Psoriasis." 2015

"A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Tazarotene Cream 0.05% (XXXX Pharmaceuticals, Inc.) to Tazorac (XXXX, LLC, Tazarotene Cream 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Plaque Psoriasis." 2014

- SCALP PSORIASIS

"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% (XXXX) to the Marketed Product Taclonex® Topical Suspension (XXXX.) in the Treatment of Scalp Psoriasis." 2017

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing XXXX Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to Reference Listed Drug in the Treatment of Scalp Psoriasis." 2017

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Shampoo in Patients with Mild to Severe Scalp Psoriasis." 2016

"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with Desoximetasone 0.25% shampoo (XXXX U.S.A., Inc.) in Patients with Scalp Psoriasis." 2016

- ROSACEA

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of XXXX in the Treatment of Papulopustular Rosacea." 2018

"A Multi-Center, Open-Label, Long-Term Safety Study of XXXX to Evaluate the Safety of XXXX in Papulopustular Rosacea Patients." 2018

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Foam 15% (XXXX) to Finacea (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2017

"A Randomized, Multi-center, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea." 2017

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (XXXX) to XXXX (Ivermectin) Cream 1% (XXXX) in the Treatment of Moderate to Severe Papulopustular Rosacea." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Topical Gel 15% (XXXX Pharmaceuticals USA, Inc) to Finacea Gel (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2016

"A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea." 2016

- ACTINIC KERATOSIS

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream 5%, With Efudex (5-FU) Cream 5%, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis." 2018

"A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% (XXXX) Compared to Solaraze® (diclofenac sodium) Gel 3% (XXXX) in the Treatment of Actinic Keratosis." 2017

"A Phase 2 Dose-Rising Study of SOR007 Ointment for Actinic Keratosis." 2017

"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects with Actinic Keratoses."

"Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.015% and Picato® Gel, 0.015% in Subjects with Actinic Keratosis on the Face or Scalp." 2016

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy with Levulan Kerastick (Aminolevulinic Acid HCL) for Topical Solution, 20% + Blue Light for the Field Treatment of Actinic Keratosis on the Face." 2016

"A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% (XXXX) Compared to Solaraze 3%, gel (diclofenac sodium 3% w/w; XXXX) in the Treatment of Actinic Keratosis." 2015

"A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% (XXXX) Compared to Solaraze 3%, gel (diclofenac sodium 3% w/w; XXXX) in the Treatment of Actinic Keratosis." 2015

"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.05% and Picato<sup>®</sup> Gel, 0.05% in Subjects with Actinic Keratosis on the Trunk or Extremities." 2015

- ATOPIC DERMATITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019

"Pilot Study of Explore LXR Receptor Engagement by ALX-101 Following Treatment of Moderate Atopic Dermatitis with ALX-101 Topical Gel and Vehicle Gel." 2018

"A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of a Topical Gel Administered Twice Daily in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis." 2017

"A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel<sup>®</sup> (Pimecrolimus) Cream, 1% in Patients with Mild to Moderate Atopic Dermatitis." 2017

"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults and Adolescents with a History of Atopic Dermatitis" 2016

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (XXXX Pharmaceuticals) to the Marketed Product ELIDEL<sup>®</sup> (pimecrolimus) Cream, 1% (XXXX Pharmaceuticals) in the Treatment of Mild to Moderate Atopic Dermatitis (AD)." 2016

"An open label, safety study to assess the potential for adrenal suppression following treatment with desoximetasone 0.15% topical spray in patients with atopic dermatitis." 2016

"A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elidel<sup>®</sup> (Pimecrolimus Cream, 1%) and Compare Both Active Ingredients to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis." 2015

- TINEA PEDIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clotrimazole and Betamethasone Dipropionate Cream 1%/0.064% (XXXX) to Lotriderm (Clotrimazole and Betamethasone Dipropionate) Cream 1%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2018

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Naftifine HCL Gel 2% (XXXX) to Naftin (Naftifine HCL) Gel, 2% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017

## Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53<sup>rd</sup> Street, Temple Terrace, FL 33617  
Office 813.948.7550 | [MooreCR.com](http://MooreCR.com) | Fax 813.948.7566

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Luliconazole Cream 1% (XXXX) to Luzu (Luliconazole) Cream, 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (XXXX, Inc.) to Econazole Nitrate Cream, 1% (XXXX.) in the Treatment of Interdigital Tinea Pedis." 2016

"A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment, Placebo Controlled, Bioequivalence Study of Naftifine Hydrochloride Cream, 2% for Topical Use with that of Naftifine (naftifine hydrochloride) Cream 2% for Topical Use in Patients with Tinea Pedis Using Clinical Endpoints." 2015

- ONYCHOMYCOSIS

"A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of Novexatin<sup>®</sup>, 10% Topical Solution (XXXX, USA, Inc.) in Patients with Mild to Moderate Onychomycosis." 2016

- INFLUENZA

"A Clinical Study to Demonstrate the Clinical Significance and Effectiveness of a Combination of Tamiflu<sup>®</sup> (Oseltamivir Phosphate) and XXX 351 versus Tamiflu<sup>®</sup> (Oseltamivir Phosphate) Alone as a Treatment for Influenza *and* the Effectiveness of a Recommended Prevention Dose of Tamiflu<sup>®</sup> (Oseltamivir Phosphate) Alone versus a Treatment of Tamiflu (Oseltamivir Phosphate) in Combination with XXX 351 as a Treatment for the Prevention of Influenza." 2015

- OSTEOARTHRITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Diclofenac Sodium Gel, 1% (XXXX) to Voltaren Gel (Diclofenac Sodium) Gel, 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Patients with Osteoarthritis of the Knee." 2017

"XXXX Product Study for the Alleviation of Pain, Inflammation and Increased Range of Motion in Patients Diagnosed with Mild to Moderate Knee Osteoarthritis; A Single-Site, Randomized, Double-Blind, Placebo-Controlled Comparative Therapeutic Clinical Study Against Osteo Bi-Flex Triple Strength." 2016